Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

Elias Jabbour, Susan O’Brien, Farhad Ravandi et al.|The Lancet Oncology|2015

Cited by 282